BioSight
Companies
Immuneering Corp logo

IMRX

NASDAQCAMBRIDGE, MA
Immuneering Corp

Immuneering develops small-molecule drug candidates, with atebimetinib (IMM-1-104) as a lead program being evaluated in clinical trials, potentially for use alone or in combination with other therapies. The excerpt provided does not contain sufficient detail about Immuneering's specific therapeutic areas or complete development stage information beyond references to ongoing and planned clinical trials.

Price history not yet available for IMRX.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar